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Bortezomib is a proteasome inhibitor used clinically for
the treatment of multiple myeloma and mantle cell lym-
phoma and is being evaluated for the treatment of
AIDS-related lymphoma and Kaposi’s sarcoma in the
AIDS Malignancy Consortium. Activation of herpes zos-
ter infection is a well-recognized complication of borte-
zomib therapy. In previous work, we have shown that
bortezomib is a potent inducer of EBV and KSHV lytic
gene expression and demonstrated a novel approach to
therapy that leverages this activation to facilitate tumor
imaging and treatment.
In an effort to better understand the relevant path-
ways, we confirmed that bortezomib at 20 nM concen-
trations induces expression of EBV and KSHV
immediate early genes (EBV ZTA, KSHV RTA) as
assessed by immunoblot and by reverse transciptase
PCR for the associated transcripts. Bortezomib activates
EBV ZTA promoter expression and KSHV RTA promo-
ter expression in reporter assays. C/EBPalpha and beta
protein family members are recognized activators of
EBV ZTA and KSHV RTA expression. Bortezomib does
not alter C/EBPalpha protein level as assessed by immu-
noblot but does lead to increased C/EBPbeta. C/EBPbeta
includes activating isoforms (LAP) and an inhibitory iso-
form (LIP). In reporter assays, we show that C/EBPbeta
LAP activates the EBV promoters whereas LIP is inhibi-
tory. In ChIP assays we show that bortezomib treatment
leads to increased C/EBPbeta binding to the ZTA pro-
moter. Mutation of the binding sites abolishes activation
of the promoter associated with bortezomib treatment.
In order to determine whether C/EBPbeta expression
simply tracks with lytic viral gene expression or plays a
key role in mediating such expression, we created a tet-
regulated C/EBPbeta knockdown. In the presence of
doxycycline, C/EBPbeta is suppressed, and bortezomib
lytic induction of EBV as measured by increases in ZTA
mRNA, ZTA protein, and viral DNA copy number are
all blunted. Induction of lytic viral gene expression in
EBV Akata cell lines by anti-Ig treatment is also
blunted.
These results suggest that C/EBPbeta family members
play a key role in mediating activation of EBV and
KSHV lytic infection following bortezomib and other
inducers.
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